BioSpace News Archive

Business

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

May 9, 2023
·
13 min read
Business

HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors

HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, announced the appointment of Nanette Cocero, Ph.D., MBA, to its Board of Directors, effective May 8, 2023.

May 9, 2023
·
2 min read
Compugen to Present at the JMP Securities Life Sciences Conference - May 09, 2023

Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that management will present at the JMP Securities Life Sciences Conference, on Tuesday, May 16, 2023 at 9:00 AM ET.

May 9, 2023
·
1 min read
Bio NC

RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced two distinct sets of new Talicia[3] data focused on generic non-bioequivalence and on dosing regimens.

May 9, 2023
·
14 min read
Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance

The Ag-Seed Division of Evogene Ltd. has announced that it has been granted a prestigious EU Horizon grant of €1.2 million, to support the creation of oil-seed crops that have high carbon-dioxide assimilation and enhanced drought tolerance.

May 9, 2023
·
8 min read
Business

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2023.

May 9, 2023
·
10 min read
Biotech Beach

Ionis to present at upcoming investor conferences - May 09, 2023

Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.

May 9, 2023
·
1 min read
Drug Development

Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that it will initiate an open-label Phase 2 exploratory trial to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy.

May 9, 2023
·
6 min read
Drug Development

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

Seres Therapeutics, Inc., a leading microbiome therapeutics company, reported initial clinical data about SER-155.

May 9, 2023
·
11 min read
Business

ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update

ADC Therapeutics SA reported financial results for the first quarter 2023 and provided an updated corporate strategy.

May 9, 2023
·
21 min read